To meet client and industry demand, we have undergone a large expansion project. This year Exelead has added two new Grade C formulations suites as well as a new filling line. The new modular filling line is a VarioSys Production System which includes a B+S filler and SKAN isolators.
All team members will be allowed to take November 3rd off (with pay) to vote in the safest way possible.
Lipid nanoparticles (LNPs) are typically seen as a niche approach to formulation, but with more complex molecules filling company pipelines, the market for LNPs is expanding rapidly. Rahul Keswani and Benjamin King are formulators at Exelead specializing in early stage LNP development. We asked for their take on the current market for LNPs.
With the rapid growth of personalized medicine and other technologies in the last five years, demand for liposomal drug products has reached an all time high. Due to the influx of business, we are excited to announce that we are beginning a large-scale expansion project that will allow us to meet industry demand and better serve our existing partners.
As part of their capstone project, this summer's crop of Exelead interns banded together to put on a 5k fundraiser for a locally-grown nonprofit. Little Red Door Cancer Agency works to reduce the physical, emotional and financial burdens of cancer for residents of central Indiana by providing free client services, cancer screenings and education.
At Exelead, we approach contract manufacturing with focused expertise on liposomal and PEGylated formulations to treat rare diseases and small or underserved populations. We specialize in the development and manufacture of lipid-based, parenteral drug products, and our team has more than 20 years' experience working with a wide range of preclinical, clinical and commercial contract manufacturing customers.